Compass Therapeutics, Inc.
CMPXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CMPX. That does not mean none is planned.
Get an email about CMPX's next catalysts
Track Compass Therapeutics (CMPX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
CTX-009
Metastatic Colorectal Cancer
Psilocybin
Post Traumatic Stress Disorder
CTX-471
Glioblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTX-009 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Psilocybin | Phase 3 | Post Traumatic Stress Disorder | - | - |
CTX-471 | Phase 2 | Glioblastoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Compass Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Compass Therapeutics, Inc.'s (CMPX) pipeline across Phase 3, Phase 2. Its lead program is CTX-009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Compass Therapeutics, Inc. (CMPX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CMPX biotech catalysts?→
Add CMPX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.